The Cutting-Edge Technology of AI Prostate Cancer Diagnosis in the Era of Digital Pathology
Digitization brought dramatic changes to the different parts of the healthcare industry. Pathology, a field in which the adoption of digitization has been quite slow compared to other fields, is now poised for the long-awaited transition to digitization. Gaining momentum as a proven and essential technology, digital pathology can be a great solution to resolve problems pathologists are facing increasing workload but not enough human resources to deal with it.
This presentation introduces an AI-powered cancer diagnostic support software for prostate cancer, the most common cancer among males. Integrated to the current workflow, the diagnostic support software can provide pathologists with meaningful benefits including minimizing the risk of human errors from the subjectivity of pathologist assessments, leading to more precise and consistent diagnostic results, and improved reproducibility.
At the same time, the talk elaborates on the cutting-edge deep learning system applied to the diagnostic software space, which overcame its limits for better performance and higher utilization.
At the end of the speech, the values of the cutting-edge technology that encompasses the entire journey of cancer care will be presented: diagnosis, prognosis, treatment.
The speech will enable the audience to gain a better understanding of the AI capabilities that can be integrated into the existing pathology workflow and change the current cancer treatment environment.
About the presenter
Sun Woo Kim, the founder and CEO of a South Korean biotech start-up, Deep Bio Inc., has a proven track record of over 20 years in executive management as well as computer science expertise. He founded the company based on the strong belief that AI can bring about positive impacts and add value to different areas of the healthcare industry. Prior to founding Deep Bio, he served as the CTO of Pinion Industries, an automotive software and security start-up, which was acquired by Hyundai Motors in 2014. He was also the deputy director of Korea Telecommunications, the largest telephone operator in Korea, where he led the global venture capital team.
Die Inhalte des Knowledge Pathway von Leica Biosystems unterliegen den Nutzungsbedingungen der Website von Leica Biosystems, die hier eingesehen werden können: Rechtlicher Hinweis. Der Inhalt, einschließlich der Webinare, Schulungspräsentationen und ähnlicher Materialien, soll allgemeine Informationen zu bestimmten Themen liefern, die für medizinische Fachkräfte von Interesse sind. Er soll explizit nicht der medizinischen, behördlichen oder rechtlichen Beratung dienen und kann diese auch nicht ersetzen. Die Ansichten und Meinungen, die in Inhalten Dritter zum Ausdruck gebracht werden, spiegeln die persönlichen Auffassungen der Sprecher/Autoren wider und decken sich nicht notwendigerweise mit denen von Leica Biosystems, seinen Mitarbeitern oder Vertretern. Jegliche in den Inhalten enthaltene Links, die auf Quellen oder Inhalte Dritter verweisen, werden lediglich aus Gründen Ihrer Annehmlichkeit zur Verfügung gestellt.
Vor dem Gebrauch sollten die Produktinformationen, Beilagen und Bedienungsanleitungen der jeweiligen Medikamente und Geräte konsultiert werden.
Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.